554 Objectives: to determine the intra-reader and inter-rater variability of the visual
interpratation of 18F-Florbetapir PET/CT regarding the positivity/negativity for amyloid …

300 Objectives The primary objective of this study was to assess the reproducibility (inter-
and intra-reader agreement) of the visual assessment of positron emission tomography …

Background Three different amyloid tracers labeled with 18-flourine have been introduced
into clinical use. The leaflets of tracers indicate different visual criteria for PET reporting. In …

Objectives An electronic training programme (ETP) was developed for interpretation of
images during routine clinical use of the PET amyloid imaging agent [18 F] flutemetamol …

Objective Amyloid positron emission tomography (PET) can reliably detect senile plaques
and fluorinated ligands are approved for clinical use. However, the clinical impact of amyloid …

1835 Objectives To compare the results of beta amyloid plaque imaging with 18F-FDG brain
imaging in patients with cognitive impairment. Methods 36 patients with a clinical history of …

Background [18 F] flutemetamol PET scanning provides information on brain amyloid load
and has been approved for routine clinical use based upon visual interpretation as either …

Purpose This study examined the feasibility of using quantitation to augment interpretation of
florbetapir PET amyloid imaging. Methods A total of 80 physician readers were trained on …

1011 Purpose: Amyloid PET/CT plays an important role in investigation of patients with
cognitive impairment and dementia, especially those with atypical and mixed clinical …

555 Objectives:[18 F] florbetaben (FBB) is approved in the EU, the USA, Japan and South
Korea for clinical use to measure beta-amyloid plaque density in adult patients with …